Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
Open accessPublished version of a preprint
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Purpose: PARP inhibitors synergize with topoisomerase inhibitors, and veliparib plus modified (m) FOLFIRI (no 5-FU bolus) had preliminary activity in metastatic pancreatic cancers. This study evaluated the safety and efficacy of second-line treatment with veliparib and mFOLFIRI versus FOLFIRI (control) for metastatic pancreatic cancer. Patients and Methods: This randomized phase II clinical trial led by the SWOG Cancer Research Network enrolled patients between September 1, 2016 and December 13, 2017. The median follow-up was 9 months (IQR 1–27). BRCA1/2 and homologous recombination DNA damage repair (HR-DDR) genetic defects were tested in blood and tumor biopsies. Patients received veliparib 200 mg twice daily, days 1–7 with mFOLFIRI days 3–5, or FOLFIRI in 14-day cycles. Results: After 123 of planned 143 patients were accrued, an interim futility analysis indicated that the veliparib arm was unlikely to be superior to control, and the study was halted. Median overall survival (OS) was 5.4 versus 6.5 months (HR, 1.23; P = 0.28), and median progression-free survival (PFS) was 2.1 versus 2.9 months (HR, 1.39; P = 0.09) with veliparib versus control. Grade 3/4 toxicities were more common with veliparib (69% vs. 58%, P = 0.23). For cancers with HR-DDR defects versus wild-type, median PFS and OS were 7.3 versus 2.5 months (P = 0.05) and 10.1 versus 5.9 months (P = 0.17), respectively, with FOLFIRI, and 2.0 versus 2.1 months (P = 0.62) and 7.4 versus 5.1 months (P = 0.10), respectively, with veliparib plus mFOLFIRI. Conclusions: Veliparib plus mFOLFIRI did not improve survival for metastatic pancreatic cancer. FOLFIRI should be further studied in pancreatic cancers with HR-DDR defects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 1×
“Pancreatic cancer is characterized by genomic instability and may harbor loss-of-function mutations in the BRCA–Fanconi anemia (FA) pathway: Breast cancer genes 1 and 2 (BRCA1 and BRCA2), partner and localizer of BRCA2 (PALB2), and FA genes (4, 5).”
BackgroundPocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Holter, S., Borgida, A., Dodd, A., Grant, R., Semotiuk, K., Hedley, D., Dhani, N., Narod, S., Akbari, M., Moore, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7401 · Cited by 398 · cited 1×
“Pancreatic cancer is characterized by genomic instability and may harbor loss-of-function mutations in the BRCA–Fanconi anemia (FA) pathway: Breast cancer genes 1 and 2 (BRCA1 and BRCA2), partner and localizer of BRCA2 (PALB2), and FA genes (4, 5).”
BackgroundWang-Gillam, A., Hubner, R. A., Siveke, J. T., Von Hoff, D. D., Belanger, B., de Jong, F. A., Mirakhur, B., & Chen, L.-T. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.007 · Cited by 342
Development of PARP and immune-checkpoint inhibitor combinations
Stewart, R. A., Pilié, P. G., & Yap, T. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-2652 · Cited by 239
Owonikoko, T. K., Dahlberg, S. E., Sica, G. L., Wagner, L. I., Wade, J. L., Srkalovic, G., Lash, B. W., Leach, J. W., Leal, T. B., Aggarwal, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00264 · Cited by 185
Research works printed but not linked: 27
- Neuzillet, 2012, FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts, World J Gastroenterol, 18, 4533, 10.3748/wjg.v18.i33.4533 · DOI
- Heeke, 2018, Prevalence of homologous recombination-related gene mutations across multiple cancer types, JCO Precis Oncol, 2018, PO.17.00286
- Ray Chaudhuri, 2012, Topoisomerase I poisoning results in PARP-mediated replication fork reversal, Nat Struct Mol Biol, 19, 417, 10.1038/nsmb.2258 · DOI · Paper page
- Smith, 2005, The novel poly (ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks, Clin Cancer Res, 11, 8449, 10.1158/1078-0432.CCR-05-1224 · DOI
- Davidson, 2013, The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines, Invest New Drugs, 31, 461, 10.1007/s10637-012-9886-7 · DOI
- Kaufman, 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation, J Clin Oncol, 33, 244, 10.1200/JCO.2014.56.2728 · DOI · Paper page
- Lowery, 2018, Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma, Eur J Cancer, 89, 19, 10.1016/j.ejca.2017.11.004 · DOI
- Shroff, 2018, Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation, JCO Precis Oncol, 2018, PO.17.00316
- Ahn, 2020, Olaparib in patients with pancreatic cancer with BRCA1/2 inactivating mutations: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study, J Clin Oncol, 38, 10.1200/JCO.2020.38.15_suppl.4637 · doi:10.1200/jco.2020.38.15_suppl.4637
- Pishvaian, 2020, A phase I/II study of veliparib (ABT-888) in combination with 5-fluorouracil and oxaliplatin in patients with metastatic pancreatic cancer, Clin Cancer Res, 26, 5092, 10.1158/1078-0432.CCR-20-1301 · DOI
- O'Reilly, 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma, Cancer, 124, 1374, 10.1002/cncr.31218 · DOI
- O'Reilly, 2020, Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation, J Clin Oncol, 38, 1378, 10.1200/JCO.19.02931 · DOI · Paper page
- Berlin, 2018, A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors, Br J Cancer, 118, 938, 10.1038/s41416-018-0003-3 · DOI
- Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 · DOI · Paper page
- Norquist, 2018, Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study, Clin Cancer Res, 24, 777, 10.1158/1078-0432.CCR-17-1327 · DOI · Paper page
- Nord, 2011, Accurate and exact CNV identification from targeted high-throughput sequence data, BMC Genomics, 12, 184, 10.1186/1471-2164-12-184 · DOI · Paper page
- LoRusso, 2016, Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with adanced solid tumors, Clin Cancer Res, 22, 3227, 10.1158/1078-0432.CCR-15-0652 · DOI
- Coleman, 2019, Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer, N Engl J Med, 381, 2403, 10.1056/NEJMoa1909707 · DOI · Paper page
- Diéras, 2020, Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomized, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 21, 1269, 10.1016/S1470-2045(20)30447-2 · DOI · Paper page
- Lord, 2017, PARP inhibitors: synthetic lethality in the clinic, Science, 355, 1152, 10.1126/science.aam7344 · DOI · Paper page
- Golan, 2021, Final overall survival results from the phase 3 POLO trial: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer, J Clin Oncol, 39, 10.1200/JCO.2021.39.3_suppl.378 · DOI
- Reiss, 2021, Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2, J Clin Oncol, 39, 2497, 10.1200/JCO.21.00003 · DOI · Paper page
- Golan, 2021, Genomic features and classification of homologous recombination–deficient pancreatic ductal adenocarcinoma, Gastroenterology, 160, 2119, 10.1053/j.gastro.2021.01.220 · DOI
- Chung, 2021, Randomized phase II trial of olaparib + pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) mutations: SWOG S2001, J Clin Oncol, 39, 10.1200/JCO.2021.39.3_suppl.TPS447 · doi:10.1200/jco.2021.39.3_suppl.tps447
- Yap, 2020, Phase I trial of the PARP inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2- and non-BRCA1/2-mutant cancers, Cancer Discov, 10, 1528, 10.1158/2159-8290.CD-20-0163 · DOI
- Prasanna, 2018, Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy, Cancer Sci, 109, 3383, 10.1111/cas.13799 · DOI
- Zheng-Lin, 2021, Pancreatic ductal adenocarcinoma in the era of precision medicine, Semin Oncol, 10.1053/j.seminoncol.2021.01.005 · DOI
Cited by
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
O’Reilly, E. M., Wainberg, Z. A., Hendifar, A. E., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G. A., Oberstein, P. E., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2605555 · Cited by 147
Self-citationDaraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer
Wolpin, B. M., Park, W., Garrido-Laguna, I., Spira, A., Starodub, A., Sommerhalder, D., Punekar, S. R., Barve, M., Pelster, M., Herzberg, B., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2505783 · Cited by 90
Self-citationTargeting DNA damage repair pathways in pancreas cancer
Crowley, F., Park, W., & O’Reilly, E. M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09983-1 · Cited by 43
Huffman, B. M., Basu Mallick, A., Horick, N. K., Wang-Gillam, A., Hosein, P. J., Morse, M. A., Beg, M. S., Murphy, J. E., Mavroukakis, S., Zaki, A., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.49720 · Cited by 25
Metadata
- Authors
- Chiorean, E. G., Guthrie, K. A., Philip, P. A., Swisher, E. M., Jalikis, F., Pishvaian, M. J., Berlin, J., Noel, M. S., Suga, J. M., Garrido-Laguna, I., Cardin, D. B., Radke, M. R., Duong, M., Bellasea, S., Lowy, A. M., & Hochster, H. S.
- Venue
- Clinical Cancer Research
- Published
- 2021-12-01
- Volume
- 27
- Issue
- 23
- Pages
- 6314-6322
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W3204487449
- Cited by
- 56
- References
- 9
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- National Institutes of Health (CA180888, CA180819, CA180820, CA180821, CA233230, CA189821, CA180818, CA189830, CA189856, CA189858, CA180826, CA190002, CA189957, CA180828, CA189971, CA180835, CA189809, CA46368, CA189960, CA180834, CA239767, CA189860, CA189861, CA189854, CA189872, CA189958, CA180801, CA189848)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-1789
- The paper
- Chiorean, E. G., Guthrie, K. A., Philip, P. A., Swisher, E. M., Jalikis, F., Pishvaian, M. J., Berlin, J., Noel, M. S., Suga, J. M., Garrido-Laguna, I., Cardin, D. B., Radke, M. R., Duong, M., Bellasea, S., Lowy, A. M., & Hochster, H. S. (2021). Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-1789
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.